BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forde KA, Bhattacharya D. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. Curr Treat Options Infect Dis 2017;9:262-76. [PMID: 29805320 DOI: 10.1007/s40506-017-0124-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Majid A, Khan S, Siraj S, Haleem S, ul Haq N, Ullah R, Ali EA, Mustafa A, Hussain H, Sohaib M. Emergence of resistance against direct acting antivirals in chronic HCV patients: A real-world study. Saudi Journal of Biological Sciences 2021. [DOI: 10.1016/j.sjbs.2021.12.044] [Reference Citation Analysis]
2 Eckardt P, Niu J, Savage A, Griffin T, Sherman E. Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital. J Int Assoc Provid AIDS Care 2019;18:2325958219835590. [PMID: 30922148 DOI: 10.1177/2325958219835590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hagiya H, Koyama T, Deguchi M, Minato Y, Miura S, Funahashi T, Teratani Y, Zamami Y, Shinomiya K, Kitamura Y, Sendo T, Hinotsu S, Kano M. Trends in hepatitis C virus-associated mortality rates in Japan, 1998-2017. J Gastroenterol Hepatol 2021. [PMID: 33837565 DOI: 10.1111/jgh.15517] [Reference Citation Analysis]